PRAM

Active material: Citalopram
When ATH: N06AB04
CCF: Antidepressant
When CSF: 02.02.04
Manufacturer: LANNACHER HEILMITTEL Ges.m.b.H. (Austria)

Pharmaceutical form, composition and packaging

Pills, covered shell white, round, lenticular.

Excipients: mannitol, microcrystalline cellulose, silica colloidal anhydrous, magnesium stearate, gipromelloza, Titanium dioxide, macrogol 6000.

10 PC. – blisters (1) – packs cardboard.

Pills, coated white, round, lenticular, with Valium.

Excipients: mannitol, microcrystalline cellulose, silica colloidal anhydrous, magnesium stearate, gipromelloza, Titanium dioxide, macrogol 6000.

10 PC. – blisters (1) – packs cardboard.

Pills, coated white, round, lenticular, with Valium.

Excipients: mannitol, microcrystalline cellulose, silica colloidal anhydrous, magnesium stearate, gipromelloza, Titanium dioxide, macrogol 6000.

10 PC. – blisters (1) – packs cardboard.

Pharmacological action

Antidepressant.

In animal studies in vitro and in vivo shows ability vsokoseleguo inhibit return neironalny taking serotonin in the central nervous system with minimal effect in respect of reverse takeover norarenalina and dopamine. Antidepressant effect is a 2-4 week of treatment.

If ingestion is the maximum concentration is achieved through 2-4 o'clock.

Pharmacokinetics

Pharmacokinetics is linear, dose-dependent nature when taking a single and repeated doses.

At reception 1 times a day equilibrium concentration in the plasma is through 1-2 weeks of therapy, and 2,5 times higher than the concentration in the blood after taking a single dose.

The volume of distribution is approximately 12 l / kg. Penetrates into breast milk.

Metabolised mainly in the liver by demethylation, deamination, oxidation with formation of demetilcitaloprama (DCT) and didemetilcitaloprama (DDCT), citalopram-N-oxide and dezaminirovannogo propionic acid derivative.

Final elimination half-life is 35 hours. Report kidneys and gut.

Testimony

• Depression different etiology.

Dosage regimen

Individual. Strictly on doctor's prescription.

Side effect

Drowsiness, fatiguability, fever, insomnia, alarm, anorexia, ažitaciâ, dysmenorrhoea, decreased libido, zevota; dry mouth, povyshenaaja sweating; tremor; nausea, diarrhea, dyspepsia, vomiting, abdominal pain; arthralgia, myalgia; upper respiratory tract infection, rhinitis, sinusitis; abnormal ejaculation, impotence.

Contraindications

• hypersensitivity,
• simultaneous MAO inhibitors.

Restrictions apply: pregnancy, lactation, childhood.

Pregnancy and lactation

The drug should be taken with extreme caution, with restriction.

Cautions

Should consider the possibility of hyponatremia, and the syndrome of inappropriate secretion of ADH, taking place at the termination of treatment and / or medical intervention.

Caution is needed, as when receiving other antidepressants, with a history of seizures.

Due to the possibility of suicide attempts in patients with depression requires careful monitoring of patients in the early treatment and appointment of the minimum effective dose to reduce the risk of overdose.

Need to be careful when working with potentially dangerous machinery, incl. while driving.

You should use caution in diseases, associated with impaired metabolism or hemodynamic.

Caution must be used together with other drugs central action.

Overdose

Symptoms: dizziness, increased perspiration, nausea, vomiting, tremor, drowsiness, sinus tachycardia. In more rare cases, amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, raʙdomioliz, ECG changes.

Treatment: Gastric lavage and the use of activated carbon. Keeping the airway to ensure adequate ventilation and oxygenation. It is recommended that careful observation and monitoring of vital functions, incl. cardiac function, symptomatic and supportive therapy. Because of the large volume of distribution of citalopram is unlikely the effectiveness of such measures, as a forced diuresis, dialysis, hemoperfusion and exchange transfusion. The specific antidote is absent.

Drug Interactions

Concomitant use with MAO inhibitors may increase the pressure and excitement.

Citalopram may enhance the effects of sumatriptan and other serotonergic agents, increases the level of metoprolol plasma and plasma concentrations of the active metabolite of imipramine.

Zimetidin increases the AUC and maximum konuentraciju citalopram.

There were no clinically significant interaction with digoxin, varfarinom, karʙamazepinom, triazolamom, ketoconazole, lithium and alcohol.

Conditions and terms

Shelf life – 3 year.